Are weight fluctuations commonly reported with Cosentyx?
No, weight fluctuations are not commonly reported with Cosentyx (secukinumab), an IL-17 inhibitor used for psoriasis, psoriatic arthritis, ankylosing spondylitis, and other inflammatory conditions. Clinical trials and post-marketing data list weight gain or loss as infrequent adverse events, occurring in less than 1-2% of patients.[1][2]
What do clinical trial data show on weight changes?
In pivotal trials like FUTURE 1-5 for psoriatic arthritis and MEASURE for ankylosing spondylitis, weight gain over 1% of body weight was reported in 1-5% of Cosentyx users versus 1-3% on placebo, with no significant difference. Severe cases (over 10% gain) were rare, under 1%.[1][3] Long-term extensions up to 5 years showed stable weight trends, without fluctuations as a standout issue.
What do patients report in real-world use?
User reviews on platforms like Drugs.com and WebMD mention weight changes sporadically—about 2-4% of over 1,000 Cosentyx reviews note minor gain (5-10 lbs) or loss, often tied to lifestyle shifts like improved mobility from reduced joint pain rather than the drug itself. Forums like PatientsLikeMe echo this, with most users reporting no weight impact.[4][5]
Why might some experience weight changes anyway?
Indirect factors play a role: reduced inflammation can boost appetite or activity levels, leading to gain in some. Others report loss from nausea (1-3% incidence) or gastrointestinal side effects.[2] No causal mechanism links Cosentyx directly to metabolic shifts, unlike steroids.
How does this compare to other biologics?
| Drug | Weight Gain Frequency | Notes |
|------|-----------------------|-------|
| Cosentyx | <2% | Minimal reports[1] |
| Humira (adalimumab) | 2-5% | Slightly higher in RA trials[6] |
| Stelara (ustekinumab) | 1-3% | Similar low rate[7] |
| Enbrel (etanercept) | 3-7% | More common in long-term use[6] |
Cosentyx has one of the lowest profiles among IL inhibitors and TNF blockers.
Should patients worry about weight with Cosentyx?
Monitor if you have obesity or metabolic conditions, but it's not a red flag. Consult your doctor for personalized risks, as individual responses vary.[2]
Sources
[1]: Novartis Cosentyx Prescribing Information
[2]: FDA Label for Secukinumab
[3]: NEJM MEASURE-1 Trial
[4]: Drugs.com Cosentyx Reviews
[5]: WebMD User Ratings
[6]: Drugs.com Humira vs. Cosentyx Comparison
[7]: Janssen Stelara PI